[A22-107] Enfortumab vedotin (urothelial carcinoma) – Addendum to Commission A22-61
Last updated 01.12.2022
Project no.:
A22-107
Commission:
Commission awarded on 11.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-61 | Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.